Kedaara Capital.
The discipline franchise of Indian PE: Fund IV ($1.74bn) raised in four months at near-100% re-up, Vishal Mega Mart monetised for ₹18,000 Cr+ post-listing, Aavas sold to CVC, and a stated posture for 2026: 'sell more, buy less'.
GW GP Score
Kedaara is what LPs mean by institutional India PE: three founders (ex-Temasek, ex-General Atlantic) intact since 2011, a CD&R-style operating model, and fundraises that close in months on re-ups. The realisation machine is running flat out: VMM's ₹8,000 Cr all-OFS IPO followed by ₹18,000 Cr+ of block sales, Aavas exited to CVC at ₹3,425 Cr, Lenskart trimmed at ~7x. Fund IV deployment tilts hard to enterprise AI/tech (Impetus $350M, Axtria $240M, Juspay, Porter) plus a consumer-healthcare platform. Kejriwal's own words frame the cycle: tolerance for risk factors cut from five to one or two. Spandana (48% held, MFI crisis) is the visible wound.
Re-up candidate: the realised-cash evidence is doing more work than the brand story.
Portfolio quality depends on a narrow theme; the right comp is concentration risk, not headline unicorn count.
No named analyst override yet; current view is generated from the scored dossier and should be refreshed when the next primary source lands.
Tynor Orthotics: reported majority, final terms unconfirmed.
Spandana resolution path.
Spandana's ~48% is a concentrated regulatory-credit wound with no clean exit path visible.
Computed from current dossier sources; analyst override pending.
The growth desk's benchmark: fastest raises, hardest selling discipline, boldest AI deployment, graded on observed behaviour where numbers stay private.
VMM/Lenskart listed winners, Perfios >26%, fresh AI platform bets; Spandana scar
₹26,000 Cr+ VMM programme + Aavas to CVC + Lenskart OFS: relentless, into strength
The clearest enterprise-AI conviction in Indian PE, plus healthcare platform
Fund IV in four months at near-100% subscription
Three founders, 15 years, zero churn found
Portfolio quality 25% · Exit realisation 30% · Sector positioning 15% · Capital velocity 15% · Franchise stability 15%: see the full GP Score methodology · compare this firm →
Positive catalysts and/or re-up evidence exceed the visible risks, but the score should move only after the named proof lands.
Lenskart liquidity clears with credible OFS/block-sale evidence.
Spandana resolution path.
Tynor Orthotics: reported majority, final terms unconfirmed.
Kedaara's four-month, re-up-driven raises mean access is the constraint, not conviction. The diligence edge: ask how Spandana is marked, and whether the AI entries (Impetus at $350M+) priced discipline or FOMO.
Spandana's ~48% is a concentrated regulatory-credit wound with no clean exit path visible.
Tynor Orthotics: reported majority, final terms unconfirmed.
Coverage initiated: inaugural GW GP Score.
Catalyst exposure · latest source pressure
Recent public evidence mapped to this GP. Read this before reading the position table: it is where the score can move next.
Keep the file warm; current events cut both ways or are not yet material enough to move score.
Attribution0 positive catalyst(s), 0 pressure catalyst(s); top driver: monthly refresh only.
The funds
$6bn+ across four funds across 3 tracked vehicles.
| Vehicle | Vintage | Size | Stage | Note |
|---|---|---|---|---|
| Fund IV | 2024Recovery / IPO window | $1.74bn | Control + growth | Then-largest independent India PE fund; Cleveland Clinic, U. Minnesota among new LPs |
| Fund III | 2021Peak frenzy | ~$1.1bn | Control + growth | Raised mid-COVID |
| Funds I-II | 2013 / 2017Foundation era | $540M / $750M | Control + growth | OTPP anchor; Temasek, Abu Dhabi seed LPs |
Closest booksADIA (India) (2 shared) · Kenro Capital (1 shared) · Oister Global (1 shared)computed · E
Fund analytics · LP underwriting screen
Computed from the public dossier: vehicle cadence, realised exits, mark drift, concentration and franchise stability. All computed signals are GW estimates.
Vehicle cadence is neither freshly restocked nor visibly stale.
Next liquidityLenskart · Perfios · Axis Finance
5 visible exit events since Jul 2024.
Vehicle cadence is neither freshly restocked nor visibly stale.
10 up / 0 flat / 1 down tracked signals.
No senior departure flagged in key people.
10 up / 0 flat / 1 down
5 events since Jul 2024
Largest tracked active exposure
Higher spread = less balanced franchise
Marked overhangSpandana Sphoorty: names with negative 12-month mark or momentum signals in the reconstructed book.
Exit-led repricing; entry discipline decisive
Cycle-top entry marks; the vintage still being digested
Pre-unicorn pricing; discovery-cost entries
Sold 73.6 lakh shares in the Nov 2025 IPO (~7x gross on 2019 entry, E); remainder held
>26% holder alongside Warburg and Bessemer; ~$500M IPO planned
First external investor in the Axis Bank NBFC: pre-IPO anchor
At least one cited source is dated 2026.
5 visible events tracked.
11 representative positions tracked.
No departure signal structured.
Fund-level DPI/TVPI is usually not public; proxy remains estimated.
Peer median 4 · +2
Peer median 4 · -1
Peer median 91 · +1
Peer median 66 · +17
Peer median 0 · +0
Diligence agenda · how this view can change
The live research question, the proof required, and the source standard. This prevents a GP score from becoming a stale label.
Team data evidence remains low-confidence despite a scored dossier.
Current · At least one cited source is dated 2026.
Upgrade the weak fields with dated facts before the next score action: Team data.
Prioritise filings and firm disclosures; mark estimates as GW E until then.
Spandana resolution path.
Lenskart: next public-market or secondary print
Evidence quality · source file health
How hard the public record is beneath this view: source mix, freshness, low-confidence fields and the next source action.
Low-confidence fields: Team data.
5 total sources · 20% primary
At least one cited source is dated 2026.
Mint: Kejriwal: 'sell more, buy less' (Jun 2026)
Upgrade Team data evidence before changing the score.
Source tiering follows Gravitywell policy: primary = filing/regulator/company disclosure, secondary = reputable media or research, E = Gravitywell estimate. Evidence score is a GW control metric, not an external rating.
The position book
Concentrated control/growth book with the CD&R operating partnership. 11 tracked below.
| Company | Sector | Entered | Entry stage | Status | 12-mo signal | Latest read |
|---|---|---|---|---|---|---|
| Vishal Mega Mart | Consumer & Commerce | 2018 | Buyout (~₹5,000 Cr w/ Partners Group) | Public | ▲ | Listed Dec 2024 at $4.3bn; staged blocks took Samayat 74.6% → 40.1%: implied >5x gross with residual (E) |
| Lenskart | Consumer & Commerce | 2019 | ₹392 Cr Series F at ~$1.15bn | Public | ▲ | Sold 73.6 lakh shares in the Nov 2025 IPO (~7x gross on 2019 entry, E); remainder held |
| Perfios | Fintech | 2023 | $229M Series D (mostly secondary) | Unicorn | ▲ | >26% holder alongside Warburg and Bessemer; ~$500M IPO planned |
| Impetus Technologies | AI | 2025 | $350M+ strategic | Private | ▲ | Data/analytics/enterprise AI: Fund IV's anchor tech bet |
| Axtria | AI | 2025 | $240M strategic | Unicorn | ▲ | Life-sciences analytics |
| Juspay | Fintech | 2025 | $60M Series D led | Unicorn | ▲ | Third tracked holder (WestBridge, SoftBank): valuation more than doubled |
| Porter | Logistics & Infra | 2025 | $200M Series F co-led | Unicorn | ▲ | With Wellington at $1.1-1.2bn: bought what Peak XV harvested at 11x |
| Purplle | Consumer & Commerce | 2021 | $75M led | Unicorn | ▲ | ADIA led the 2024 rounds at $1.25bn pre |
| K12 Techno (Orchids Schools) | Consumer & Commerce | 2023 | Growth | Private | ▲ | Kenro's $40M 2024 entry provided co-investor liquidity; Kedaara remains |
| Axis Finance | Fintech | 2026 | ₹750 Cr for 5% | Private | ▲ | First external investor in the Axis Bank NBFC: pre-IPO anchor |
| Spandana Sphoorty | Fintech | 2017 | Rescue → ~48% | Public | ▼ | ₹601 Cr net loss, MFI stress: the book's open wound |
Representative tracked positions reconstructed from public disclosures: not the full book. 12-mo signal is a GW estimate of mark direction from round/exit prints (E). Ownership stakes are not shown: not reliably public.
Sector exposure · where the book leans
Share of the tracked active book by normalized sector (GW estimate): read against our sector dossiers for crowding.
New cheques · 2025-26
Fund IV's deployment is the clearest enterprise-AI conviction in Indian PE: $650M+ into Impetus/Axtria/Juspay in twelve months, layered over a consumer-healthcare platform (Oasis, ASG, Tynor) and pre-IPO financial-services anchoring (Axis Finance). All under a stated tighter bar: approve three or four deals where ten once passed.
Consumer-healthcare platform build
Realisation · are LPs getting paid?
The most aggressive listed-position monetisation in Indian PE this cycle: VMM alone returned ₹26,000 Cr+ across IPO and blocks (shared), executed into strength. Sell-more-buy-less isn't rhetoric: it's the observed behaviour. Ami Lifesciences' ~par promoter buyback and Spandana's markdown keep the ledger honest.
~14% for ₹7,635 Cr: cumulative ~33.8% sold post-listing for ₹18,000 Cr+ (with Partners Group).
73.6 lakh shares in the OFS (~₹296 Cr, E); ~7x gross vs the 2019 entry (E).
20.2% for ₹10,488 Cr: upsized from plan; Samayat to 54.4%.
₹8,000 Cr, 100% OFS at $4.3bn valuation.
26.47% to CVC for ₹3,425 Cr (with Partners Group): full exit of the 2016 carve-out.
The cleanest LP verdict in Indian PE
>5x gross implied on the 2018 entry, residual 40% still held (E)
MFI-crisis exposure; GS3 5.25%
Signals excellent; numbers private
No published DPI, but the observable chain, four-month raises, 80% re-ups, systematic block-selling into strength, is what top-quartile behaviour looks like from outside. GW read: the highest-conviction franchise signal on the growth desk. E.
What they're doing
Operating-heavy control PE with the CD&R partnership: buy well, operate, sell into strength.
Enterprise-AI/tech as the Fund IV theme: Impetus, Axtria, Juspay, Porter, Neurealm.
Consumer-healthcare platform assembly (Oasis, ASG, Tynor) with a dedicated group CEO.
Cycle discipline stated and observed: 'sell more, buy less' as private marks lag public corrections.
What can break
Spandana's ~48% is a concentrated regulatory-credit wound with no clean exit path visible.
Enterprise-AI entries at 2025-26 prices carry the cycle's premium: the discipline creed meets its test here.
Founder-trio key-person concentration; no publicised succession layer beneath.
Tynor Orthotics: reported majority, final terms unconfirmed.
Spandana resolution path.
Perfios IPO (DRHP not yet filed).
VMM residual 40%: further blocks reported under consideration.
Point-in-time discipline: these are the open items we could not verify at the current vintage. They get resolved: confirmed, corrected or dropped, at the next monthly refresh, never silently.
The takes · one screen, three readers
Kedaara's four-month, re-up-driven raises mean access is the constraint, not conviction. The diligence edge: ask how Spandana is marked, and whether the AI entries (Impetus at $350M+) priced discipline or FOMO.
Kedaara is now the exit bid for your growth positions (Porter from Peak XV's book) AND the seller setting listed-consumer supply (VMM blocks). Its stated risk-bar tightening telegraphs where it WON'T compete: broad seed-adjacent growth.
The VMM sell-down calendar is the single biggest supply overhang in listed Indian retail; Perfios and Axis Finance are the fintech-infra prints to watch next.
Sourcing. Every figure is sourced and dated. We tier provenance: Primary (official, regulatory, exchange or company filings), Secondary (tier-1 industry research and reputable media), and GW estimate (our own reconstruction or opinion, labelled, never presented as external fact). We prefer primary where it exists, reconcile divergent prints to cited ranges, and hold every number point-in-time: dated, and never silently restated; revisions publish as dated changes.
Fact vs opinion. Facts vs opinion: market sizes, official prints, prices, named deals and agency ratings are sourced facts (Primary/Secondary). Scores, grades, purity weights, scenario paths and indicative sparkline points are Gravitywell's analytical opinion (GW estimate): labelled, not presented as external data.
GW GP Scores are research opinions, not investment advice, not a solicitation, and not an assessment under any SEBI regulation. Dossiers are compiled from public sources believed reliable; firms named did not participate and figures marked E are Gravitywell estimates. Point-in-time: dated to the vintage shown and never silently restated.